{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T07:59:30Z","timestamp":1740124770451,"version":"3.37.3"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,1,12]],"date-time":"2022-01-12T00:00:00Z","timestamp":1641945600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,12]],"date-time":"2022-01-12T00:00:00Z","timestamp":1641945600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Obes"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1038\/s41366-021-01062-3","type":"journal-article","created":{"date-parts":[[2022,1,12]],"date-time":"2022-01-12T04:51:13Z","timestamp":1641963073000},"page":"918-925","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["E4orf1-induced reduction in endogenous insulin level is independent of pancreas endocrine function"],"prefix":"10.1038","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4639-5581","authenticated-orcid":false,"given":"Md","family":"Akheruzzaman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4160-2764","authenticated-orcid":false,"given":"Vijay","family":"Hegde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Md Abu Bakkar","family":"Siddik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7116-0923","authenticated-orcid":false,"given":"Zahra","family":"Feizy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4748-5135","authenticated-orcid":false,"given":"Andrew C.","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1356-1064","authenticated-orcid":false,"given":"Nikhil V.","family":"Dhurandhar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,12]]},"reference":[{"key":"1062_CR1","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1038\/nature05482","volume":"444","author":"SE Kahn","year":"2006","unstructured":"Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 2006;444:840\u20136.","journal-title":"Nature."},{"key":"1062_CR2","doi-asserted-by":"publisher","first-page":"533","DOI":"10.2147\/DMSO.S146339","volume":"11","author":"R Sarwar","year":"2018","unstructured":"Sarwar R, Pierce N, Koppe S. Obesity and nonalcoholic fatty liver disease: current perspectives. Diabetes Metab Syndr Obesity. 2018;11:533.","journal-title":"Diabetes Metab Syndr Obesity"},{"key":"1062_CR3","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/nature05487","volume":"444","author":"LF Van Gaal","year":"2006","unstructured":"Van Gaal LF, Mertens IL, Christophe E. Mechanisms linking obesity with cardiovascular disease. Nature. 2006;444:875\u201380.","journal-title":"Nature."},{"key":"1062_CR4","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.cmet.2007.12.009","volume":"7","author":"MS Brown","year":"2008","unstructured":"Brown MS, Goldstein JL. Selective versus total insulin resistance: a pathogenic paradox. Cell Metabol. 2008;7:95\u20136.","journal-title":"Cell Metabol"},{"key":"1062_CR5","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/S0140-6736(13)62154-6","volume":"383","author":"SE Kahn","year":"2014","unstructured":"Kahn SE, Cooper ME, Del Prato S. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet. 2014;383:1068\u201383.","journal-title":"Lancet"},{"key":"1062_CR6","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1038\/nature05488","volume":"444","author":"J-P Despr\u00e9s","year":"2006","unstructured":"Despr\u00e9s J-P, Lemieux I. Abdominal obesity and metabolic syndrome. Nature. 2006;444:881\u20137.","journal-title":"Nature."},{"key":"1062_CR7","doi-asserted-by":"publisher","first-page":"431","DOI":"10.2337\/diacare.25.3.431","volume":"25","author":"I Janssen","year":"2002","unstructured":"Janssen I, Fortier A, Hudson R, Ross R. Effects of an energy-restrictive diet with or without exercise on abdominal fat, intermuscular fat, and metabolic risk factors in obese women. Diabetes Care. 2002;25:431\u20138.","journal-title":"Diabetes Care"},{"key":"1062_CR8","doi-asserted-by":"publisher","first-page":"373","DOI":"10.2147\/DMSO.S13860","volume":"3","author":"R Dalle Grave","year":"2010","unstructured":"Dalle Grave R, Calugi S, Centis E, Marzocchi R, El Ghoch M, Marchesini G. Lifestyle modification in the management of the metabolic syndrome: achievements and challenges. Diabetes Metab Syndr Obesity. 2010;3:373.","journal-title":"Diabetes Metab Syndr Obesity"},{"key":"1062_CR9","first-page":"452","volume":"7","author":"BR Miller","year":"2014","unstructured":"Miller BR, Nguyen H, Hu CJ-H, Lin C, Nguyen QT. New and emerging drugs and targets for type 2 diabetes: reviewing the evidence. American health & drug benefits. 2014;7:452.","journal-title":"American health & drug benefits"},{"key":"1062_CR10","doi-asserted-by":"publisher","first-page":"3606","DOI":"10.2174\/1381612821666150710145753","volume":"21","author":"MJ Meneses","year":"2015","unstructured":"Meneses MJ, Silva BM, Sousa M, Sa R, Oliveira PF, Alves MG. Antidiabetic drugs: Mechanisms of action and potential outcomes on cellular metabolism. Current pharmaceutical design. 2015;21:3606\u201320.","journal-title":"Current pharmaceutical design"},{"key":"1062_CR11","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jdiacomp.2012.09.006","volume":"27","author":"NV Dhurandhar","year":"2013","unstructured":"Dhurandhar NV. Insulin sparing action of adenovirus 36 and its E4orf1 protein. Journal of Diabetes and its Complications. 2013;27:191\u20139.","journal-title":"Journal of Diabetes and its Complications"},{"key":"1062_CR12","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1038\/s41366-020-0526-6","volume":"44","author":"Z Feizy","year":"2020","unstructured":"Feizy Z, Peddibhotla S, Khan S, Hegde V, Wang S, Dhurandhar NV. Nanoparticle-mediated in vitro delivery of E4orf1 to preadipocytes is a clinically relevant delivery system to improve glucose uptake. International Journal of Obesity. 2020;44:1607\u201316.","journal-title":"International Journal of Obesity"},{"key":"1062_CR13","doi-asserted-by":"publisher","first-page":"358","DOI":"10.2337\/db16-0876","volume":"66","author":"TB McMurphy","year":"2017","unstructured":"McMurphy TB, Huang W, Xiao R, Liu X, Dhurandhar NV, Cao L. Hepatic expression of adenovirus 36 E4ORF1 improves glycemic control and promotes glucose metabolism through AKT activation. Diabetes. 2017;66:358\u201371.","journal-title":"Diabetes."},{"key":"1062_CR14","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.molmet.2015.07.004","volume":"4","author":"CM Kusminski","year":"2015","unstructured":"Kusminski CM, Gallardo-Montejano VI, Wang ZV, Hegde V, Bickel PE, Dhurandhar NV, et al. E4orf1 induction in adipose tissue promotes insulin-independent signaling in the adipocyte. Mol Metabol. 2015;4:653\u201364.","journal-title":"Mol Metabol"},{"key":"1062_CR15","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.2337\/db07-1313","volume":"57","author":"ZQ Wang","year":"2008","unstructured":"Wang ZQ, Cefalu WT, Zhang XH, Yu Y, Qin J, Son L, et al. Human adenovirus type 36 enhances glucose uptake in diabetic and nondiabetic human skeletal muscle cells independent of insulin signaling. Diabetes. 2008;57:1805\u201313.","journal-title":"Diabetes."},{"key":"1062_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41387-020-0114-9","volume":"10","author":"M Akheruzzaman","year":"2020","unstructured":"Akheruzzaman M, Hegde V, Shin AC, Dhurandhar NV. Reducing endogenous insulin is linked with protection against hepatic steatosis in mice. Nutrition Diabetes. 2020;10:1\u201312.","journal-title":"Nutrition Diabetes"},{"key":"1062_CR17","doi-asserted-by":"publisher","unstructured":"Mostofinejad Z, Akheruzzaman M, Abu Bakkar Siddik M, Patkar P, Dhurandhar NV, Hegde V. Antidiabetic E4orf1 protein prevents hepatic steatosis and reduces markers of aging-related cellular damage in high fat fed older mice. BMJ Open Diabetes Res Care. 2021;9:e002096. https:\/\/doi.org\/10.1136\/bmjdrc-2020-002096.","DOI":"10.1136\/bmjdrc-2020-002096"},{"key":"1062_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41387-019-0085-x","volume":"9","author":"S Peddibhotla","year":"2019","unstructured":"Peddibhotla S, Hegde V, Akheruzzaman M, Dhurandhar NV. E4orf1 protein reduces the need for endogenous insulin. Nutr Diabetes. 2019;9:1\u20139.","journal-title":"Nutr Diabetes"},{"key":"1062_CR19","doi-asserted-by":"publisher","first-page":"3732","DOI":"10.1172\/JCI126309","volume":"129","author":"LF Barella","year":"2019","unstructured":"Barella LF, Rossi M, Zhu L, Cui Y, Mei FC, Cheng X, et al. \u03b2 Cell\u2013intrinsic \u03b2-arrestin 1 signaling enhances sulfonylurea-induced insulin secretion. J Clin Investig. 2019;129:3732\u20137.","journal-title":"J Clin Investig"},{"key":"1062_CR20","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/0014-2999(87)90737-0","volume":"143","author":"G Skoglund","year":"1987","unstructured":"Skoglund G, Lundquist I, Ahr\u00e9n B. \u03b11-and \u03b12-adrenoceptor activation increases plasma glucagon levels in the mouse. Eur J Pharmacol. 1987;143:83\u20138.","journal-title":"Eur J Pharmacol"},{"key":"1062_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13578-017-0198-7","volume":"8","author":"Y Yang","year":"2018","unstructured":"Yang Y, Liu X, Liu Y, Fu H, Gao Y, Liu X, et al. The development of salt-sensitive hypertension regulated by PSGL-1 gene in mice. Cell Biosci. 2018;8:1\u20137.","journal-title":"Cell Biosci"},{"key":"1062_CR22","doi-asserted-by":"publisher","first-page":"212","DOI":"10.3164\/jcbn.09-83","volume":"46","author":"JC Fraulob","year":"2010","unstructured":"Fraulob JC, Ogg-Diamantino R, Fernandes-Santos C, Aguila MB, Mandarim-de-Lacerda CA. A mouse model of metabolic syndrome: insulin resistance, fatty liver and non-alcoholic fatty pancreas disease (NAFPD) in C57BL\/6 mice fed a high fat diet. J Clin Biochem Nutr. 2010;46:212\u201323.","journal-title":"J Clin Biochem Nutr"},{"key":"1062_CR23","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1046\/j.1463-1326.2003.00239.x","volume":"5","author":"S Fischer","year":"2003","unstructured":"Fischer S, Patzak A, Rietzsch H, Schwanebeck U, K\u00f6hler C, Wildbrett J, et al. Influence of treatment with acarbose or glibenclamide on insulin sensitivity in type 2 diabetic patients. Diabetes Obesity Metab. 2003;5:38\u201344.","journal-title":"Diabetes Obesity Metab"},{"key":"1062_CR24","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.2337\/diacare.25.8.1271","volume":"25","author":"LS Cozma","year":"2002","unstructured":"Cozma LS, Luzio SD, Dunseath GJ, Langendorg KW, Pieber T, Owens DR. Comparison of the effects of three insulinotropic drugs on plasma insulin levels after a standard meal. Diabetes Care. 2002;25:1271\u20136.","journal-title":"Diabetes Care"},{"key":"1062_CR25","doi-asserted-by":"crossref","unstructured":"Rosol TJ, DeLellis RA, Harvey PW, Sutcliffe C. Chapter 58\u2014Endocrine system. In: Haschek WM, Rousseaux CG, Wallig MA, editors. Haschek and Rousseaux\u2019s handbook of toxicologic pathology, 3rd edn. Boston: Academic Press; 2013. p. 2391\u2013492.","DOI":"10.1016\/B978-0-12-415759-0.00058-3"},{"key":"1062_CR26","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1093\/jmcb\/mjaa009","volume":"12","author":"J Guo","year":"2020","unstructured":"Guo J, Fu W. Immune regulation of islet homeostasis and adaptation. J Mol Cell Biol. 2020;12:764\u201374.","journal-title":"J Mol Cell Biol"},{"key":"1062_CR27","doi-asserted-by":"publisher","unstructured":"Dhurandhar EJ, Krishnapuram R, Hegde V, Dubuisson O, Tao R, Dong XC, et al. E4orf1 improves lipid and glucose metabolism in hepatocytes: a template to improve steatosis & hyperglycemia. PLoS ONE. 2012;7:e47813. https:\/\/doi.org\/10.1371\/journal.pone.0047813.","DOI":"10.1371\/journal.pone.0047813"},{"key":"1062_CR28","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.cell.2014.06.005","volume":"158","author":"JC Lo","year":"2014","unstructured":"Lo JC, Ljubicic S, Leibiger B, Kern M, Leibiger IB, Moede T, et al. Adipsin is an adipokine that improves \u03b2 cell function in diabetes. Cell. 2014;158:41\u201353.","journal-title":"Cell."},{"key":"1062_CR29","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.2147\/DMSO.S253967","volume":"13","author":"GG Tafere","year":"2020","unstructured":"Tafere GG, Wondafrash DZ, Zewdie KA, Assefa BT, Ayza MA. Plasma Adipsin as a Biomarker and Its Implication in Type 2 Diabetes Mellitus. Diabetes Metab Syndr Obes. 2020;13:1855\u201361.","journal-title":"Diabetes Metab Syndr Obes"}],"container-title":["International Journal of Obesity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41366-021-01062-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41366-021-01062-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41366-021-01062-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T23:06:23Z","timestamp":1651187183000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41366-021-01062-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,12]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["1062"],"URL":"https:\/\/doi.org\/10.1038\/s41366-021-01062-3","relation":{},"ISSN":["0307-0565","1476-5497"],"issn-type":[{"type":"print","value":"0307-0565"},{"type":"electronic","value":"1476-5497"}],"subject":[],"published":{"date-parts":[[2022,1,12]]},"assertion":[{"value":"2 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"NVD has received several patents in viral obesity and adenovirus 36, including uses for E1A, E4ORF1 gene and protein, and AKT1inhibitor, and has received past grant support from Vital Health Interventions for determining anti-diabetic properties of E4\u2010ORF1 protein. Drs. Dhurandhar and Hegde recently received funding from Insparin Inc, which is a company created to advance the development of E4orf1 as a therapeutic agent. NVD owns shares in Insparin Ins. Funding from Insparin was not received for this study. Other authors did not have any conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}